Colivicchi, Furio <br/><br/>
Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries.  [electronic resource] 

 -  Cardiovascular therapeutics  2020 
 - 3856242 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1755-5922 
<br/><br/><label>Standard No.: </label>10.1155/2020/3856242  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anticholesteremic Agents--adverse effects<br/>Biomarkers--blood<br/>Cholesterol, LDL--blood<br/>Clinical Decision-Making<br/>Down-Regulation<br/>Dyslipidemias--blood<br/>Eligibility Determination--trends<br/>Female<br/>Humans<br/>Italy--epidemiology<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--diagnosis<br/>PCSK9 Inhibitors<br/>Patient Selection<br/>Practice Patterns, Physicians'--trends<br/>Prospective Studies<br/>Registries<br/>Secondary Prevention--trends<br/>Serine Proteinase Inhibitors--adverse effects<br/>Time Factors<br/>Treatment Outcome